Panelists discuss how atopic dermatitis affects not only the child’s comfort and confidence but also family well-being and emotional health.

Panelists discuss how treatment goals should center on the child’s comfort, sleep quality, and emotional well-being, not just visible skin improvement.

Panelists discuss how individualized, consistent topical care helps build trust, promotes adherence, and prevents disease flare-ups in children with AD.

Panelists discuss how corticosteroids remain essential for controlling flares but must be used thoughtfully with education and reassurance for families.

Panelists discuss how calcineurin inhibitors can be safely and effectively used in children with proper education and clinical oversight.

Panelists discuss how nonsteroidal PDE-4 and JAK inhibitors offer effective, targeted relief while addressing caregiver concerns about safety and chronic use.

Panelists discuss how individualized strategies combining steroids, nonsteroidal agents, and caregiver education promote sustained disease control in children.

Panelists discuss how unmet needs in topical care highlight the importance of safe, simple, and effective long-term therapies for children with AD.

Panelists discuss how improved clinical trial design helps ensure new treatments reflect real-world experiences and family priorities.

Panelists discuss how clinical results confirm the effectiveness, safety, and caregiver convenience of new nonsteroidal therapies for pediatric AD.

Panelists discuss how low systemic absorption and simple dosing schedules improve safety, adherence, and caregiver confidence in pediatric AD care.

Panelists discuss how evidence from clinical studies supports the safety and effectiveness of new nonsteroidal treatments for children with AD.

Panelists discuss how JAK-targeting topical therapies offer effective, well-tolerated solutions for children with mild to moderate AD.

Panelists discuss how new nonsteroidal therapies improve adherence, comfort, and long-term skin health for children with AD.